JPRN-UMIN000021349已完成未知
Feasibility of Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a pilot study. - Feasibility of Ruxolitinib in steroid-refractory GVHD
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 2
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 70years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) with active infection 2) w/o informed consent 3) CCr<10 ml/min
研究者
相似试验
已完成
2 期
First Line Therapy for High Risk Acute GVHDaGVHDStem Cell Transplant ComplicationsNCT04061876Chinese PLA General Hospital198
进行中（未招募）
1 期
Immediate corticosteroid therapy and rituximab to prevent generalization in ocular myasthenia gravis: a PROBE-type multicenter, open-label, randomized controlled trialMyasthenia gravisCTIS2023-506656-24-00Hopital Fondation Adolphe De Rothschild128
进行中（未招募）
不适用
Therapy for elderly or unfit leukemia patientsTreated Elderly Patients with Chronic B Lymphocytic Leukemia or patients with underlying pathologyMedDRA version: 15.1Level: LLTClassification code 10003948Term: B-Lymphocytic, CLL (Kiel Classification) refractorySystem Organ Class: 100000004864MedDRA version: 15.1Level: LLTClassification code 10003947Term: B-Lymphocytic, CLL (Kiel Classification) recurrentSystem Organ Class: 100000004864EUCTR2010-023205-35-LTVilnius University Hospital Santariskiu Clinics
已完成
2 期
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)Graft-versus-host Disease (GVHD)NCT02953678Incyte Corporation71
进行中（未招募）
不适用
Rituximab treatment in patients with tjyroid associated that do not respond to intravenous steroids or relapse after intravenous steroid treatmentThyroid associated opthalmopathyEUCTR2011-000899-33-SEDepartment of Endocrinology, Sahlgrenska University Hospital50